Module 1: Introduction:  Dr Mayuri Keskar from MLH welcome the participants and panelists, then Dr A.K. Singh, Secretary ICS UP shared insights on TB situation. He then welcome the speakers and then invited Dr Digamber Behera to share his knowledge on Guidelines for management of drug resistance TB. First poll was raised.

Module 2: Guidelines for management of drug resistance TB:Padma Shri, Professor, Dr. Digambar Behera, General Medicine/Respiratory Medicine, started his session by sharing the global and national magnitude of drug resistance TB. He covered following points during his session:

•          Focus on MDRTB
•          Methods of DRT and DST
•          Definition of DRTB
•          Evolution of DRTB
•          Causes of DRTB
•          Milestones in evolution of PMDT in India
•          National DR Survey- DST summary
•          Status of DRTB service in India
•          Treatment success rate of MDR TB patient & different regimens
•          National strategic plan 2017-25 for ending TB in India
•          Prevention of DRTB
•          Grouping of anti TB drugs
•          Sustaining and improving quality of DRTB care
•          Patient centric care
•          Customized treatment with patient support
•           Points to remember
•          Dimensions of TB
•          DRTB regimen and various TB management regimen
•          Adverse drug reaction
•          Salvage regimen with Bedaquiline & Delamanid

Module 3: Use of Delamanid:Dr. Surya Kant Professor And Head, Department Of Respiratory Medicine, KGMU continued the session by sharing the details on drug management of MDR TB. During the session he explained about following points in detail:

•          Classes of anti TB drugs recommended for treatment of DRTB
•          Introduction and details about Delamanid
•          Bactericidal cycle
•          Special features of Delamanid
•          Indications of Delamanid
•          Inclusion criteria, exclusion criteria
•          Doses of Delamanid
•          Scope of Delamanid in MDR / XDR TB
•          Sequence of using replacement of drugs to modify longer oral MDR / XDR TB regimen
•          Specific toxicity
•          Drug drug interaction
•          Studies of Delamanid

Module 4: Q&A session:Several questions were asked during thesession which were asked by Dr A K Singh to speakers. Almost all the answers were answered by the speakers during the session

Module 5: Vote of Thanks:After speakers and Q&A session Dr A K Singh from ICS UP & Dr Mayuri Keskar from MLH shared vote of thanks with all panelist, participants and sponsors for supporting in the event.

We wish you a great learning experience and we thank Mylan Pharmaceuticals Private Limited, a Viatris Company for supporting us in the webinar